Predictive values of gynaecological cancer alarm symptoms in a general population

Aim: The aim of this study was to determine predictive values of gynaecological alarm symptoms in the general population. Materials and Methods: A population-based prospective cohort study combining questionnaire data with register data of gynaecological cancer and premalignant conditions in a one-year follow-up period. Results: Among 25,866 women, some 2,957 (11.4%) reported at least one newly onset gynaecological cancer alarm symptom within a four-week time period. A total of 71 women were diagnosed with a gynaecological cancer or a premalignant condition. The positive predictive values (PPVs) ranged between 0.1% (95%-CI: 0.1-0.1) for cancer among women reporting at least one of the 18 unspecific and specific gynaecological cancer alarm symptoms and 0.3% (95%-CI: 0.2-0.4) for dysplasia among women reporting at least one of the specific alarm symptoms that lead to a GP contact. The positive likelihood ratios (LR+s) ranged between 0.9 (95%-CI: 0.7;1.2) for cancer among women reporting at least one unspecific symptom and 1.7 (95%-CI: 1.1-2.5) for dysplasia among women reporting at least one specific alarm symptom. Conclusion: The PPVs and LR+s of gynaecological alarm symptoms in the general population are very low, and only few of the patients diagnosed with gynaecological cancer reported specific alarm symptoms. Thus targeted diagnosis of gynaecological cancer cannot be based on cancer alarm symptoms only.

Gynaecological cancer; Predictive values; Alarm symptoms; General population; Questionnaire; Denmark

[1] Statens Serum Institut: “Tal og Analyse: Cancerregisteret 2013 [Figures and Analyses: The Danish Cancer Registry 2013]”. Copenhagen, 2014.

[2] Karim-Kos H.E., de Vries E., Soerjomataram I., Lemmens V., Siesling S., Coebergh J.W.: “Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s”. Eur. J. Cancer, 2008, 44, 1345.

[3] Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al.: “Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data”. Lancet, 2011, 377, 127.

[4] Neal R.D., Tharmanathan P., France B., Din N.U., Cotton S., Fallon- Ferguson J., et al.: “Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review”. Br. J. Cancer, 2015, 112, S92.

[5] Maringe C., Walters S., Butler J., Coleman M.P., Hacker N., Hanna L., et al.: “Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership”. Gynecol. Oncol., 2012, 127, 75.

[6] The Danish National Board of Health: “National cancer plan II”. Copenhagen: National Board of Health, 2005.

[7] National Institute for Health and Clinical Excellence: “Referral guidelines for suspected cancer”. London: NICE, 2005.

[8] Buchanan EM, Weinstein LC, Hillson C. “Endometrial cancer”. Am. Fam. Physician, 2009, 80, 1075.

[9] Goff B.: “Symptoms associated with ovarian cancer”. Clin. Obstet. Gynecol., 2012, 55, 36.

[10] Shapley M., Jordan J., Croft P.R.: “A systematic review of postcoital bleeding and risk of cervical cancer”. Br. J. Gen. Pract., 2006, 56, 453.

[11] Balasubramaniam K., Ravn P., Larsen P.V., Sondergaard J., Jarbol D.E.: “Specific and unspecific gynecological alarm symptoms - prevalence estimates in different age groups: a population-based study”. Acta Obstet. Gynecol. Scand., 2015, 94, 191.

[12] Low E.L., Simon A.E., Waller J., Wardle J., Menon U.: “Experience of symptoms indicative of gynaecological cancers in UK women”. Br. J. Cancer, 2013, 109, 882.

[13] Rasmussen S., Sondergaard J., Larsen P.V., Balasubramaniam K.: “The Danish Symptom Cohort: Questionnaire and Feasibility in the Nationwide Study on Symptom Experience and Healthcare-Seeking among 100 000 Individuals”. Int. J. Family Med., 2014, 2014, 187280.

[14] Rambøll Management Consulting: SurveyXact”. 2012. Available at: https://www.surveyxact.com

[15] de Vet H.C.W., Terwee C.B., Mokkink L.B., Knol D.L.: “Measurement in Medicine - A practical guide”. Cambridge: Cambridge University Press, 2011.

[16] The Danish National Board of Health: “Pakkeforløb for kræft i æggestokkene [Cancer package for ovarian cancer]”. Copenhagen, 2011.

[17] The Danish National Board of Health: “Pakkeforløb for livmoderhalskræft [Cancer package for cervical cancer]”. Copenhagen, 2012.

[18] The Danish National Board of Health: “Pakkeforløb for kræft i livmoderen [Cancer package for endometrial cancer]”. Copenhagen: National Board of Health, 2012.

[19] National Institute for Health and Clinical Excellence: “The recognition and initial management of ovarian cancer”. London: NICE, 2011.

[20] Gjerstorff M.L.: “The Danish Cancer Registry”. Scand. J. Public Health, 2011, 39, 42.

[21] Huggenberger I.K., Andersen J.S.: “Predictive value of the official cancer alarm symptoms in general practice - a systematic review”. Dan. Med. J., 2015, 62, pii: A5034.

[22] Walker S., Hyde C., Hamilton W.: “Risk of uterine cancer in symptomatic women in primary care: case-control study using electronic records”. Br. J. Gen. Pract., 2013, 63, e643.

[23] Hamilton W., Peters T.J., Bankhead C., Sharp D.: “Risk of ovarian cancer in women with symptoms in primary care: population based case-control study”. BMJ, 2009, 339, b2998.

[24] Thompson, Pond, Ellis, Beach, Thompson: “Rectal bleeding in general and hospital practice; ‘the tip of the iceberg’”. Colorectal Dis.. 2000, 2, 288.

[25] Nielsen T.N., Hansen R.P., Vedsted P.: “Symptom presentation in cancer patients in general practice”. Ugeskr Laeger., 2010, 172, 2827.

[26] Scheel B.I., Ingebrigtsen S.G., Thorsen T., Holtedahl K.: “Cancer suspicion in general practice: the role of symptoms and patient characteristics, and their association with subsequent cancer”. Br. J. Gen. Pract., 2013, 63, e627.

[27] Rai N., Nevin J., Downey G., Abedin P., Balogun M., Kehoe S., et al.: “Outcomes following implementation of symptom triggered diagnostic testing for ovarian cancer”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2015, 187, 64.